Prenetics Global Limited announced a strong Q1 2026 with total revenue of $36 million, driven by IM8's $33.8 million revenue, a 23.1% increase from Q4 2025 and nearly sixfold year-over-year growth. IM8's monthly revenue hit a record $16.7 million in May, implying an annualized recurring revenue of about $200 million. The company raised its full-year 2026 IM8 revenue guidance to $190-$210 million and projects Q2 revenue of $46-$48 million. Strategic moves include expanding IM8's global reach to 43 countries, launching new product lines in Q4 2026, and strengthening leadership with a new CFO appointment. Prenetics also maintains a strong, debt-free balance sheet and continues share repurchases, signaling confidence in long-term growth.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
